
浏览全部资源
扫码关注微信
1.陆军军医大学(第三军医大学)第一附属医院放射科,重庆
2.推想医疗科技股份有限公司,北京
3.陆军特色医学中心(第三军医大学大坪医院)放射科,重庆
4.东部战区总医院放射诊断科,江苏南京
陈 伟,E-mail:landcw@tmmu.edu.cn
收稿日期:2024-11-05,
修回日期:2025-01-09,
纸质出版日期:2025-04-30
移动端阅览
杨涛涛,王显棋,陈灿灿,等.基于CT影像组学特征联合临床特征预测非小细胞肺癌EGFR突变状态[J].陆军军医大学学报,2025,47(08):847-857.
YANG Taotao,WANG Xianqi,CHEN Cancan,et al.Prediction of EGFR mutation status in non-small cell lung cancer based on CT radiomic features combined with clinical characteristics[J].J Army Med Univ,2025,47(08):847-857.
杨涛涛,王显棋,陈灿灿,等.基于CT影像组学特征联合临床特征预测非小细胞肺癌EGFR突变状态[J].陆军军医大学学报,2025,47(08):847-857. DOI:10.16016/j.2097-0927.202411024.
YANG Taotao,WANG Xianqi,CHEN Cancan,et al.Prediction of EGFR mutation status in non-small cell lung cancer based on CT radiomic features combined with clinical characteristics[J].J Army Med Univ,2025,47(08):847-857. DOI:10.16016/j.2097-0927.202411024.
目的
2
探究基于胸部CT影像组学特征联合临床特征预测非小细胞肺癌(non-small cell lung cancer, NSCLC)表皮生长因子受体(epidermal growth factor receptor, EGFR)基因突变的预测价值。
方法
2
采用病例对照研究的方法,收集2013年1月至2023年10月3家医疗中心放射科1 070名NSCLC患者的临床信息和CT图像。其中陆军军医大学第一附属医院719名NSCLC患者按照7∶3的比例随机分成训练集、内部验证集;东部战区总医院173名患者、陆军特色医学中心178名患者分别作为外部验证集1、外部验证集2。使用最小绝对收缩和选择算子回归筛选最佳影像组学特征,构建影像组学模型;以单因素及多因素Logistic回归筛选EGFR突变相关的临床特征,构建临床模型;联合影像组学特征及临床特征构建综合模型。3种分类模型均采用随机森林(random forest, RF)的机器学习方法进行建模。采用曲线下面积(AUC)、准确率、敏感度和特异度评价模型预测效能。绘制校正曲线以评估综合模型的拟合优度,决策曲线评估模型的临床应用价值。
结果
2
影像组学模型在内部验证集、外部验证集1、外部验证集2中的AUC值分别为0.762 4(95%
CI
: 0.692 4~0.825 1)、0.745 4(95%
CI
: 0.671 1~0.814 3)和0.724 7(95%
CI
: 0.639 7~0.801 6);临床预测模型在内部验证集、外部验证集1、外部验证集2的AUC值分别为0.691 7(95%
CI
: 0.627 9~0.757 6)、0.652 5(95%
CI
: 0.576 7~0.729 1)和0.779 2(95%
CI
: 0.712 5~0.847 3);基于临床特征和影像组学特征构建的综合模型预测效能值最佳,其在内部验证集、外部验证集1、外部验证集2的AUC值分别为0.818 0(95%
CI
: 0.757 7~0.874 3)、0.782 4(95%
CI
: 0.7031~0.848 2)和0.796 6(95%
CI
: 0.718 1~0.868 6)。校准曲线提示综合模型拟合度较好,决策曲线提示综合模型具有较好的净收益。
结论
2
结合胸部CT影像组学特征与临床特征构建的综合模型在预测NSCLC EGFR基因突变的多中心数据集中表现出更好的预测性能,有助于帮助临床制定治疗策略。
SUNG H , FERLAY J , SIEGEL R L , et al . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin , 2021 , 71 ( 3 ): 209 - 249 . DOI: 10.3322/caac.21660 http://dx.doi.org/10.3322/caac.21660 .
URAS I Z , MOLL H P , CASANOVA E . Targeting KRAS mutant non-small-cell lung cancer: past, present and future [J]. Int J Mol Sci , 2020 , 21 ( 12 ): 4325 . DOI: 10.3390/ijms21124325 http://dx.doi.org/10.3390/ijms21124325 .
OSOEGAWA A , TAKUMI Y , HASHIMOTO T , et al . Cyclin-dependent kinase (CDK) 4/6 inhibition in non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutations [J]. Invest New Drugs , 2023 , 41 ( 2 ): 183 - 192 . DOI: 10.1007/s10637-023-01337-8 http://dx.doi.org/10.1007/s10637-023-01337-8 .
ETTINGER D S , WOOD D E , AISNER D L , et al . Non-small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology [J]. J Natl Compr Canc Netw , 2017 , 15 ( 4 ): 504 - 535 . DOI: 10.6004/jnccn.2017.0050 http://dx.doi.org/10.6004/jnccn.2017.0050 .
HOSOMI Y , MORITA S , SUGAWARA S , et al . Gefitinib alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 study [J]. J Clin Oncol , 2020 , 38 ( 2 ): 115 - 123 . DOI: 10.1200/JCO.19.01488 http://dx.doi.org/10.1200/JCO.19.01488 .
MITSUDOMI T , MORITA S , YATABE Y , et al . Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial [J]. Lancet Oncol , 2010 , 11 ( 2 ): 121 - 128 . DOI: 10.1016/S1470-2045(09)70364-X http://dx.doi.org/10.1016/S1470-2045(09)70364-X .
MAEMONDO M , INOUE A , KOBAYASHI K , et al . Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR [J]. N Engl J Med , 2010 , 362 ( 25 ): 2380 - 2388 . DOI: 10.1056/NEJMoa0909530 http://dx.doi.org/10.1056/NEJMoa0909530 .
ZITO MARINO F , BIANCO R , ACCARDO M , et al . Molecular heterogeneity in lung cancer: from mechanisms of origin to clinical implications [J]. Int J Med Sci , 2019 , 16 ( 7 ): 981 - 989 . DOI: 10.7150/ijms.34739 http://dx.doi.org/10.7150/ijms.34739 .
SALLER J J , BOYLE T A . Molecular pathology of lung cancer [J]. Cold Spring Harb Perspect Med , 2022 , 12 ( 3 ): a037812 . DOI: 10.1101/cshperspect.a037812 http://dx.doi.org/10.1101/cshperspect.a037812 .
RIOS VELAZQUEZ E , PARMAR C , LIU Y , et al . Somatic mutations drive distinct imaging phenotypes in lung cancer [J]. Cancer Res , 2017 , 77 ( 14 ): 3922 - 3930 . DOI: 10.1158/0008-5472.CAN-17-0122 http://dx.doi.org/10.1158/0008-5472.CAN-17-0122 .
GARINET S , LUPO A , DENIZE T , et al . Successive next-generation sequencing strategy for optimal fusion gene detection in non-small-cell lung cancer in clinical practice [J]. Pathology , 2024 , 56 ( 5 ): 702 - 709 . DOI: 10.1016/j.pathol.2024.02.014 http://dx.doi.org/10.1016/j.pathol.2024.02.014 .
LAMBIN P , RIOS-VELAZQUEZ E , LEIJENAAR R , et al . Radiomics: extracting more information from medical images using advanced feature analysis [J]. Eur J Cancer , 2012 , 48 ( 4 ): 441 - 446 . DOI: 10.1016/j.ejca.2011.11.036 http://dx.doi.org/10.1016/j.ejca.2011.11.036 .
JIANG L , YOU C , XIAO Y , et al . Radiogenomic analysis reveals tumor heterogeneity of triple-negative breast cancer [J]. Cell Rep Med , 2022 , 3 ( 7 ): 100694 . DOI: 10.1016/j.xcrm.2022.100694 http://dx.doi.org/10.1016/j.xcrm.2022.100694 .
WANG Z P , FANG M J , ZHANG J , et al . Radiomics and deep learning in nasopharyngeal carcinoma: a review [J]. IEEE Rev Biomed Eng , 2024 , 17 : 118 - 135 . DOI: 10.1109/RBME.2023.3269776 http://dx.doi.org/10.1109/RBME.2023.3269776 .
WANG T T , SHE Y L , YANG Y , et al . Radiomics for survival risk stratification of clinical and pathologic stage IA pure-solid non-small cell lung cancer [J]. Radiology , 2022 , 302 ( 2 ): 425 - 434 . DOI: 10.1148/radiol.2021210109 http://dx.doi.org/10.1148/radiol.2021210109 .
KHORRAMI M , PRASANNA P , GUPTA A , et al . Changes in CT radiomic features associated with lymphocyte distribution predict overall survival and response to immunotherapy in non-small cell lung cancer [J]. Cancer Immunol Res , 2020 , 8 ( 1 ): 108 - 119 . DOI: 10.1158/2326-6066.CIR-19-0476 http://dx.doi.org/10.1158/2326-6066.CIR-19-0476 .
YIN X M , LIAO H , YUN H , et al . Artificial intelligence-based prediction of clinical outcome in immunotherapy and targeted therapy of lung cancer [J]. Semin Cancer Biol , 2022 , 86 ( Pt 2 ): 146 - 159 . DOI: 10.1016/j.semcancer.2022.08.002 http://dx.doi.org/10.1016/j.semcancer.2022.08.002 .
HUANG B , SOLLEE J , LUO Y H , et al . Prediction of lung malignancy progression and survival with machine learning based on pre-treatment FDG-PET/CT [J]. EBioMedicine , 2022 , 82 : 104127 . DOI: 10.1016/j.ebiom.2022.104127 http://dx.doi.org/10.1016/j.ebiom.2022.104127 .
RAMI-PORTA R , ASAMURA H , TRAVIS W D , et al . Lung cancer-major changes in the American Joint Committee on Cancer eighth edition cancer staging manual [J]. CA Cancer J Clin , 2017 , 67 ( 2 ): 138 - 155 . DOI: 10.3322/caac.21390 http://dx.doi.org/10.3322/caac.21390 .
ZHOU J Y , ZHENG J , YU Z F , et al . Comparative analysis of clinicoradiologic characteristics of lung adenocarcinomas with ALK rearrangements or EGFR mutations [J]. Eur Radiol , 2015 , 25 ( 5 ): 1257 - 1266 . DOI: 10.1007/s00330-014-3516-z http://dx.doi.org/10.1007/s00330-014-3516-z .
ZHANG G J , ZHANG J , CAO Y T , et al . Nomogram based on preoperative CT imaging predicts the EGFR mutation status in lung adenocarcinoma [J]. Transl Oncol , 2021 , 14 ( 1 ): 100954 . DOI: 10.1016/j.tranon.2020.100954 http://dx.doi.org/10.1016/j.tranon.2020.100954 .
YATABE Y , KERR K M , UTOMO A , et al . EGFR mutation testing practices within the Asia Pacific region: results of a multicenter diagnostic survey [J]. J Thorac Oncol , 2015 , 10 ( 3 ): 438 - 445 . DOI: 10.1097/jto.0000000000000422 http://dx.doi.org/10.1097/jto.0000000000000422 .
LIU Y , KIM J , QU F Y , et al . CT features associated with epidermal growth factor receptor mutation status in patients with lung adenocarcinoma [J]. Radiology , 2016 , 280 ( 1 ): 271 - 280 . DOI: 10.1148/radiol.2016151455 http://dx.doi.org/10.1148/radiol.2016151455 .
DU W X , QIU T , LIU H Q , et al . The predictive value of serum tumor markers for EGFR mutation in non-small cell lung cancer patients with non-stage IA [J]. Heliyon , 2024 , 10 ( 9 ): e29605 . DOI: 10.1016/j.heliyon.2024.e29605 http://dx.doi.org/10.1016/j.heliyon.2024.e29605 .
SHUI L , REN H Y , YANG X , et al . The era of radiogenomics in precision medicine: an emerging approach to support diagnosis, treatment decisions, and prognostication in oncology [J]. Front Oncol , 2021 , 10 : 570465 . DOI: 10.3389/fonc.2020.570465 http://dx.doi.org/10.3389/fonc.2020.570465 .
SAAD M B , HONG L Z , AMINU M , et al . Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study [J]. Lancet Digit Health , 2023 , 5 ( 7 ): e404 - e420 . DOI: 10.1016/S2589-7500(23)00082-1 http://dx.doi.org/10.1016/S2589-7500(23)00082-1 .
ZHANG X P , ZHANG G J , QIU X T , et al . Exploring non-invasive precision treatment in non-small cell lung cancer patients through deep learning radiomics across imaging features and molecular phenotypes [J]. Biomark Res , 2024 , 12 ( 1 ): 12 . DOI: 10.1186/s40364-024-00561-5 http://dx.doi.org/10.1186/s40364-024-00561-5 .
LI X M , CHEN J W , ZHANG C X , et al . Application value of CT radiomic nomogram in predicting T790M mutation of lung adenocarcinoma [J]. BMC Pulm Med , 2023 , 23 ( 1 ): 339 . DOI: 10.1186/s12890-023-02609-y http://dx.doi.org/10.1186/s12890-023-02609-y .
TU W T , SUN G Y , FAN L , et al . Radiomics signature: a potential and incremental predictor for EGFR mutation status in NSCLC patients, comparison with CT morphology [J]. Lung Cancer , 2019 , 132 : 28 - 35 . DOI: 10.1016/j.lungcan.2019.03.025 http://dx.doi.org/10.1016/j.lungcan.2019.03.025 .
LI Y J , LU L , XIAO M J , et al . CT slice thickness and convolution kernel affect performance of a radiomic model for predicting EGFR status in non-small cell lung cancer: a preliminary study [J]. Sci Rep , 2018 , 8 ( 1 ): 17913 . DOI: 10.1038/s41598-018-36421-0 http://dx.doi.org/10.1038/s41598-018-36421-0 .
LIU Y , KIM J , BALAGURUNATHAN Y , et al . Radiomic features are associated with EGFR mutation status in lung adenocarcinomas [J]. Clin Lung Cancer , 2016 , 17 ( 5 ): 441 - 448.e6 . DOI: 10.1016/j.cllc.2016.02.001 http://dx.doi.org/10.1016/j.cllc.2016.02.001 .
0
浏览量
0
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621